Presenter of 1 Presentation
EFFECTIVENESS OF MY DOSE COACH (MDC) USE DURING BASAL INSULIN (BI) TITRATION IN TYPE 2 DIABETES (T2D): REAL-WORLD DATA FROM ALGERIA, COLOMBIA, INDIA AND MEXICO
Abstract
Background and Aims
This retrospective cohort study evaluated the effectiveness of MDC, an FDA-approved BI dose titration app, use with BI on clinical outcomes.
Methods
People with T2D on BI therapy, who registered from 01/08/2018 through 30/09/2021 and recorded ≥2 fasting blood glucose (FBG) readings in the MDC app over a 2-week period were included in this analysis. FBG target achievement (≥3 consecutive measurements within the target range), change in FBG, and hypoglycemia (readings below HCP-defined cut-off per dose plan) were assessed.
Results
A total of 5,566 MDC users (Algeria, 881; Colombia, 505; India, 2,597; and Mexico, 1,583) with mean (SD) age 54.7 (13.8) years (~50% female) were included. Overall, 3,097 (55.6%) achieved individualized FBG target and mean time to reach target was 15.6 days. The proportion of patients achieving FBG target was highest in Columbia (81.0%) and lowest in India (39.9%). Mean FBG decreased by 36.4 mg/dL (~22%), and mean BI dose increased by 4 U (21.7%). The initial FBG value and FBG mean reduction were highest in India; whereas mean BI dose (U) increase was highest in Mexico. Hypoglycemia events were reported in 783 (14%) participants overall. Incidence of hypoglycemia was comparable across countries (Table).
Conclusions
More than 50% of the MDC users were able to successfully titrate their BI and achieve target FBG, demonstrating the potential application of MDC during insulin titration to improve diabetes management particularly in a resource-limited setting.